无偏细胞表面蛋白质组学鉴定SEMA4A为骨髓瘤有效免疫治疗靶点
研究对原代人骨髓瘤细胞进行质膜蛋白质组学分析,鉴定出大量细胞表面蛋白,并用新方法优先筛选免疫治疗靶点,发现此前未与骨髓瘤关联的SEMA4A。通过shRNA和CRISPR/dCas9敲低证实SEMA4A表达对骨髓瘤细胞体外正常生长必需,且标准CRISPR/Cas9敲除筛选因外显子跳跃无法将其识别为治疗靶点。最终用新型抗体药物偶联物在体外和体内高效选择性靶向SEMA4A。
要点
- 原代人骨髓瘤细胞质膜蛋白质组学鉴定出大量细胞表面蛋白。
- SEMA4A表达对骨髓瘤细胞体外正常生长必需。
- 标准CRISPR/Cas9敲除筛选因外显子跳跃无法识别SEMA4A为靶点。
核心结论
- SEMA4A是骨髓瘤细胞生长所必需且可被新型抗体药物偶联物在体外和体内高效选择性靶向的细胞表面蛋白。
研究设计与样本
- 对原代人骨髓瘤细胞进行质膜蛋白质组学分析,并使用新方法优先筛选免疫治疗靶点。
- 采用短发夹RNA和CRISPR/核酸酶失活Cas9(dCas9)敲低验证SEMA4A功能。
- 使用新型抗体药物偶联物在体外和体内靶向SEMA4A。
主要发现
- 质膜蛋白质组学鉴定出原代人类骨髓瘤细胞大量细胞表面蛋白。
- 短发夹RNA和CRISPR/dCas9敲低显示SEMA4A表达是骨髓瘤细胞体外正常生长所必需。
- 标准CRISPR/Cas9敲除筛选因外显子跳跃不会将SEMA4A识别为骨髓瘤治疗靶点。
- 新型抗体药物偶联物在体外和体内高效且选择性地靶向SEMA4A。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The accessibility of cell surface proteins makes them tractable for targeting by cancer immunotherapy, but identifying suitable targets remains challenging. Here we describe plasma membrane profiling of primary human myeloma cells to identify an unprecedented number of cell surface proteins of a primary cancer. We used a novel approach to prioritize immunotherapy targets and identified a cell surface protein not previously implicated in myeloma, semaphorin-4A (SEMA4A). Using knock-down by short-hairpin RNA and CRISPR/nuclease-dead Cas9 (dCas9), we show that expression of SEMA4A is essential for normal myeloma cell growth in vitro, indicating that myeloma cells cannot downregulate the protein to avoid detection. We further show that SEMA4A would not be identified as a myeloma therapeutic target by standard CRISPR/Cas9 knockout screens because of exon skipping. Finally, we potently and selectively targeted SEMA4A with a novel antibody-drug conjugate in vitro and in vivo.
引用
- Anderson GSF, Ballester-Beltran J, Giotopoulos G, et al. Unbiased cell surface proteomics identifies SEMA4A as an effective immunotherapy target for myeloma. Blood. 2022. PMID: 35134130. doi:10.1182/blood.2021015161
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。